GOETTINGEN, Germany--(BUSINESS WIRE)--Regulatory News: Extraordinary effects, especially de-stocking measures, at leading US biopharma-ceutical companies affected the supplier industry in North America, mainly during the first half of 2008. Thus, revenue growth for the Sartorius Stedim Biotech Group (SSB) was soft for the fiscal year. In Europe, sales showed solid development; in Asia, revenue growth was rather flat. Compared to the competition, SSB performed well under these adverse market conditions. Meanwhile, the above mentioned extra-ordinary effects are phasing out and the North American market environment is showing signs of improvement.
